Vetter
Vetter, a pharmaceutical service provider, is expanding its pharmaceutical warehouse in Ravensburg. The capacity expansion supports the increasing market demand as well as the organic growth of the independent family-owned company. With an investment volume of over €150 million, the existing 13,000 pallet spaces for cold storage will be expanded by a further 16,000. Once completed, Vetter will...
Vetter, a global pharmaceutical service provider, is expanding its management team. From January 2025, Thomas Otto and Peter Sölkner will join Henryk Badack, Titus Ottinger and Carsten Press in managing the family-owned company. By expanding its management team, the independent CDMO for the manufacturing of complex injectable drugs is ensuring its sustainable growth. “We at Vetter are committed to...
The contract development and manufacturing organization Vetter has successfully completed the first 100 clinical batches of liquid and lyophilized vials at its Austrian site in Rankweil. Since commissioning in 2021, Vetter Development Services Austria has been supporting the production and quality control of drug candidates for clinical trials.
Vetter is investing in the expansion of its production capacities in Germany and the USA. The pharmaceutical service provider will relocate its site for development services within the USA and continue to expand there. At the same time, in addition to the ongoing capacity expansions in Ravensburg and Langenargen, Vetter is planning to establish a further site in Saarlouis, Saarland, for the...
The pharmaceutical service provider Vetter Pharma has successfully completed eight market launches of complex medicinal products in 2023. The products were accompanied and supported during their development phases by the comprehensive services of the Vetter Development Service. The drugs, which are now on the market worldwide, are used in oncology and for the treatment of autoimmune and...
As a globally active Contract Development and Manufacturing Organization (CDMO), Vetter has joined the German Association of Research-Based Pharmaceutical Companies vfa as an associate member. With this special membership, the vfa recognizes the significant role that the pharmaceutical service provider plays in the field of complex injectable drugs. Vetter supports research-based pharmaceutical...
Vetter has been a member of the Science Based Targets Initiative (SBTi) since November 2023. The aim of the companies in the SBTi is to become climate-neutral by 2050. The initiative thus represents the strictest climate protection targets for companies worldwide. The pharmaceutical service provider has thus committed itself to the 1.5-degree target. To this end, the company has presented a...
The pharmaceutical service provider Vetter is investing over 230 million euros in a new production building at its Ravensburg site, which will house several commercial filling lines. With the completion of the 122-meter-long, 44-meter-wide and 32-meter-high shell, an important milestone has now been reached following the start of construction in November 2021. The company will thus once again...
Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), has been awarded the Frost & Sullivan’s 2023 Global Customer Value Leadership Award in the aseptic fill-and-finish market for the company’s high performance for its customers. The award, presented annually by the international growth strategy consulting firm, focuses on both business and customer impact along with...
Vetter, a globally leading contract development and manufacturing organization (CDMO), announced the commissioning of a new warehouse designed to help meet increasing customer market supply demands. With a total investment of approx. 20 million euros, the new fully automated building provides storage space for materials with high-stock turnover rates such as packaging components and thus...
